(+)-Grandiforacin, an antiausterity agent, induces autophagic PANC-1 pancreatic cancer cell death

Drug Design, Development and Therapy

Volumn 8, Issue , 2013, Pages 39-47

  Ueda, Jun Ya ^a,b   Athikomkulchai, Sirivan ^c   Miyatake, Ryuta ^b   Saiki, Ikuo ^b   Esumi, Hiroyasu ^d,e   Awale, Suresh ^a,b  

^a Frontier research core for life sciences ^*  (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c SRINAKHARINWIROT UNIVERSITY   (Thailand)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

(+) grandiforacin; Antiausterity strategy; Nutrient starvation; PANC 1

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CASPASE 3; DEOXYGLUCOSE; FLUOROURACIL; GEMCITABINE; GLUCOSE; GRANDIFLORACIN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PLANT EXTRACT; PODOPHYLLOTOXIN; PROTEIN BCL 2; UNCLASSIFIED DRUG; BRIDGED COMPOUND; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

AKT KINASE ASSAY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PANC 1 CELL LINE; PANCREAS CANCER; PANCREAS TUMOR; PHARMACODYNAMICS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STARVATION; UPREGULATION; UVARIA; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; AUTOPHAGY; BRIDGED COMPOUNDS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84890483880     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S52168     Document Type: Article

References (34)

1. Asuthkar S, Rao JS, Gondi CS. Drugs in preclinical and early-stage clinical development for pancreatic cancer. Expert Opin Investig Drugs. 2012;21:143-152.
2. The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan 2012. Tokyo, Japan: Foundation for Promotion Cancer Research; 2012.
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
4. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
5. Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer. 1995;31:882-887.
6. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest oncology group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605-3610.
7. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mes-enchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:5820-5828.
8. Qiu MT, Ding XX, Hu J W, Tian HY, Yin R, Xu L. Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials. Cancer Chemother Pharmacol. 2012;70:861-873.
9. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gem-citabine for metastatic pancreatic cancer. N Engl J Med. 2011;364: 1817-1825.
10. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554.
11. Ko AH, Venook A P, Bergsland EK, et al. A Phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010;66:1051-1057.
12. Sakamoto H, Kitano M, Suetomi Y, Maekawa K, Takeyama Y, Kudo M. Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas. Ultrasound Med Biol. 2008;34:525-532.
13. Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266-4276.
14. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res. 2000;60:6201-6207.
15. Awale S, Lu J, Kalauni SK, et al. Identifcation of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res. 2006;66:1751-1757.
16. Awale S, Nakashima EMN, Kalauni SK, et al. Angelmarin, a novel anti-cancer agent able to eliminate the tolerance of cancer cells to nutrient starvation. Bioorg Med Chem Lett. 2006;16:581-583.
17. Win NN, Awale S, Esumi H, Tezuka Y, Kadota S. Novel anticancer agents, kayeassamins A and B from the fower of Kayea assamica of Myanmar. Bioorg Med Chem Lett. 2008;18:4688-4691.
18. Win NN, Awale S, Esumi H, Tezuka Y, Kadota S. Novel anticancer agents, kayeassamins C-I from the fower of Kayea assamica of Myanmar. Bioorg Med Chem. 2008;16:8653-8660.
19. Win NN, Awale S, Esumi H, Tezuka Y, Kadota S. Bioactive secondary metabolites from Boesenbergia pandurata of Myanmar and their preferential cytotoxicity against human pancreatic cancer PANC-1 cell line in nutrient-deprived medium. J Nat Prod. 2007;70:1582-1587.
20. Win NN, Awale S, Esumi H, Tezuka Y, Kadota S. Panduratins D-I, novel secondary metabolites from rhizomes of Boesenbergia pandurata. Chem Pharm Bull. 2008;56:491-496.
21. Awale S, Linn TZ, Than MM, Swe T, Saiki I, Kadota S. The healing art of traditional medicines in Myanmar. J Trad Med. 2006;23:47-68.
22. Awale S, Ueda J, Athikomkulchai S, et al. Antiausterity agents from Uvaria dac and their preferential cytotoxic activity against human pancreatic cancer cell lines in a nutrient-deprived condition. J Nat Prod. 2012;75:1177-1183.
23. Guertin DA, Sabatini DM. Defning the role of mTOR in cancer. Cancer Cell. 2007;12:9-22.
24. Conroy T, Gavoille C, Samalin E, Ychou M, Ducreux M. The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Curr Oncol Rep. 2013;15:182-189.
25. Saif M W. Advancements in the management of pancreatic cancer: 2013. JOP. 2013;14:112-118.
26. Schönthal AH. Endoplasmic reticulum stress and autophagy as targets for cancer therapy. Cancer Lett. 2009;275:163-169.
27. Schönthal AH. Gliomas: Aggravating endoplasmic reticulum stress by combined application of bortezomib and celexoib as a novel therapeutic strategy for glioblastoma. In: Hayat MA, editor. Tumors of the Central Nervous System. Dordrecht, The Netherlands: Springer; 2011;1.
28. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011;10:1533-1541.
29. Sato K, Tsuchihara K, Fujii S, et al. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res. 2007;67:9677-9684.
30. Choi KS. Autophagy and cancer. Exp Mol Med. 2012;44:109-120.
31. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene. 2004;23:2891-2906.
32. Esumi H, Lu J, Kurashima Y, Hanaoka T. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci. 2004;95: 685-690.
33. Lu J, Kunimoto S, Yamazaki Y, Kaminishi M, Esumi H. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. Cancer Sci. 2004;95: 547-552.
34. Yardley DA. Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions. Breast Cancer Basic Res Treat. 2013;7:7-22.